EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling

Subotheni Thavaneswaran iD, Hao-Wen Sim iD, John Grady, David Espinoza, Min Li Huang, Frank Lin, Margaret McGrath, Jayesh Desai, Michail Charakidis, Michael Brown, Maya Kansara iD, John Simes und 1 weitere

The Oncologist · 04.08.2025 · 30 (8)

DOI: 10.1093/oncolo/oyae339 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 25.12.2024. Verfasst von Subotheni Thavaneswaran und 12 weiteren Autor:innen. Beteiligte Einrichtung: NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW 2050, Australia. Hauptthemen laut MEDLINE: Pyrazoles, Pyrimidines, Receptor, trkA, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

TRK-inhibitors have demonstrated efficacy across several cancers with NTRK fusions. Their activity in cancers with NTRK overexpression remains unclear.

Methods

This trial enrolled patients with advanced cancers harboring NTRK fusions or extreme mRNA overexpression, defined as NTRK1/2/3 expression by RNA profiling >5 SDs for a given cancer type. The primary endpoint was objective response rate (ORR), with secondary endpoints including time-to-progression (TTP) ratio [TTP on study to TTP on previous systemic therapy (TTP1)], progression-free survival (PFS), and overall survival (OS). Initially planned for 2 non-comparator groups: primary central nervous system (CNS) and non-CNS tumours with NTRK fusions, the protocol was amended to permit NTRK overexpression.

Results

Seventeen patients were treated with larotrectinib: one glioblastoma with a SPECC1L::NTRK2 fusion (group 1), and a peripheral nerve sheath tumor with a TPM3::NTRK1 fusion and 15 patients with overexpression (group 2). The ORR was 6%. An additional 3 of 12 (25%) TTP1-evaluable patients achieved a TTP ratio ≥1.3 and 2 of 5 without an evaluable TTP1 had a PFS >6 months. Median PFS and OS were 3.5 (95% CI, 1.4-6.0) and 15.9 months (95% CI, 6.4-NR), respectively.

Conclusion

Unlike its efficacy in NTRK-fusion positive cancers, larotrectinib did not demonstrate a signal of efficacy among tumors with NTRK overexpression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesPyrimidinesReceptor, trkANeoplasmsReceptor, trkBReceptor, trkCOncogene Proteins, FusionHumansMaleFemaleMiddle AgedAdultAgedRNA, MessengerGene Expression ProfilingMembrane Glycoproteins

Stichwörter der Autor:innen

NTRK fusionsNTRK overexpressionTRK inhibitorlarotrectinib

Substanzen

larotrectinibPyrazolesPyrimidinesReceptor, trkAReceptor, trkBReceptor, trkCRNA, MessengerNTRK1 protein, humantropomyosin-related kinase-B, humanNTRK3 protein, human

Autor:innen und Institutionen

  • NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW 2050, Australia.
  • The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW 2010, Australia.
  • School of Clinical Medicine, Faculty of Medicine and Health, University of NSW, Sydney, NSW 2010, Australia.
  • Garvan Institute of Medical Research, Sydney, NSW 2010, Australia.
  • Chris O'Brien Lifehouse, Sydney, NSW 2050, Australia.
  • SydPath Department of Anatomical Pathology, St Vincent's Hospital, Sydney, NSW 2010, Australia.

ORCID-Profile: Subotheni Thavaneswaran, Hao-Wen Sim, Maya Kansara

Zitieren

APA

Thavaneswaran, S., Sim, H. W., Grady, J., Espinoza, D., Huang, M. L., Lin, F., McGrath, M., Desai, J., Charakidis, M., Brown, M., Kansara, M., Simes, J., & Thomas, D. (2025). A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling. The Oncologist, 30(8). https://doi.org/10.1093/oncolo/oyae339

Vancouver

Thavaneswaran S, Sim HW, Grady J, Espinoza D, Huang ML, Lin F, et al. A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling. The Oncologist. 2025;30(8). doi:10.1093/oncolo/oyae339

BibTeX
@article{Thavaneswaran2025,
  author = {Thavaneswaran, Subotheni and Sim, Hao-Wen and Grady, John and Espinoza, David and Huang, Min Li and Lin, Frank and McGrath, Margaret and Desai, Jayesh and Charakidis, Michail and Brown, Michael and Kansara, Maya and Simes, John and Thomas, David},
  title = {A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {8},
  doi = {10.1093/oncolo/oyae339}
}
Kostenlos starten →